China's Biocytogen gets $78m Series D
Chinese contract research organization (CRO) Biocytogen has raised a RMB543 million ($78 million) Series D round led by China Life Insurance and SDIC Venture Capital, a VC arm of the State Development & Investment Corporation (SDIC).
Existing investors CMB International – an investment arm of China Merchants Bank – Materia Medica Capital, and 3E Bioventures also participated in the funding round, according to a release. All three...
More on Greater China
Latest News
Fund focus: Kotak exploits distressed assets edge
Kotak Mahindra Group hopes his longstanding experience in financial services will serve as a differentiator as it looks for deals in India's increasingly popular distressed space
Sovereign investors and technology: Smart nations
Conservative sovereign wealth investors are increasingly comfortable making direct commitments to venture-oriented technology companies. The strategy appears to suit them but remains to be validated
China's 01VC pursues industrial upgrade strategy
01VC has secured institutional LP support for its second fund, which closed at $100 million. The early-stage investor plans to deploy it across industrial and enterprise deals in China and Southeast Asia